Keyword: Avastin


2. Roche

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.

4. Avastin

Avastin is Roche’s third cancer blockbuster expected to come up against 2019 biosimilar competition in the U.S. Roche has billions at stake as biosims creep to the critical market.